Brought to you by 
Series E results in $55mm for Versartis
27 Feb 2014
Executive Summary
Just four months after closing a $20mm Series D financing, Versartis Inc. (working on growth hormone deficiency--GHD--treatments) raised $55mm in Series E funds from five undisclosed new backers and returning shareholders Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners, and Advent Venture Partners. The money will move its pediatric GHD candidate VRS317 into Phase III.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series E results in $55mm for Versartis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice